ACE Inhibitors Market: Global Industry Trends, Growth Drivers and Forecast
The ACE Inhibitors Market is an important segment of the global cardiovascular therapeutics industry, supported by the increasing prevalence of hypertension, heart failure, and other cardiovascular conditions. According to Market Research Future, the market was valued at USD 5.55 billion in 2024 and is projected to grow from USD 5.74 billion in 2025 to USD 8.02 billion by 2035, registering a CAGR of 3.4% during the forecast period.
ACE inhibitors are widely used for managing hypertension and heart failure and may also be prescribed for conditions such as diabetic nephropathy and myocardial infarction. Major drugs covered in the market include lisinopril, ramipril, enalapril, benazepril, fosinopril, captopril, and moexipril. Oral tablets and oral solutions represent key dosage forms.
The rising geriatric population is an important market driver because older adults have a higher prevalence of cardiovascular diseases and hypertension. Increasing awareness of cardiovascular health and improved diagnosis are also supporting demand. Pharmaceutical companies are developing improved formulations and combination therapies to enhance treatment effectiveness and patient adherence.
North America remains a major regional market, while Europe and Asia-Pacific offer significant growth opportunities. The Asia-Pacific market is benefiting from improving healthcare infrastructure, increasing healthcare expenditure, and the growing burden of hypertension.
Overall, pharmaceutical innovation, digital health integration, increasing disease awareness, and the expanding need for affordable cardiovascular treatments are expected to support continued growth in the ACE Inhibitors Market.